Barclays maintains Phathom Pharmaceuticals at Overweight, lowers price target to $10 from $14

Barclays kept its Overweight rating on Phathom Pharmaceuticals but cut its price target to $10 from $14, a 28.6% reduction. The new target suggests an 81.8% upside from the Nov 17 closing price of $5.50.

Original reporting
Published Nov 18, 2026, 2:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 2:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Phathom Pharmaceuticals at Overweight, lowers price target to $10 from $14 — source image
Decision brief

The 30-second read

$PHATBearishLow
01

Why it matters

A lower price target can influence short-term positioning and expectations, but it does not by itself change the company’s fundamentals.

02

Market read

Traders may reassess near-term valuation expectations for PHAT based on the PT cut, but there is no new operational catalyst in the text.

03

What to watch

Without any new trial, approval, or guidance detail, the market reaction may be muted and could depend on whether other analysts adjust targets in the same direction.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication date, for positioning around PT changes

Background

The piece is an analyst-maintenance update from Barclays, not a company disclosure.

Company-level read

Ticker impact

$PHATBearishMedium confidence
Context

Barclays maintained Phathom Pharmaceuticals at Overweight and cut its price target to $10 from $14, signaling reduced valuation expectations.

Expected impact

Likely mild downside pressure as traders price in the lower target, though the unchanged Overweight rating may limit selling.

Evidence & confidence

The article provides only a PT reduction with no new clinical, regulatory, or financial datapoint, so the move is sentiment-driven rather than catalyst-driven.

Market effects

Limited read-through to biotech sector fundamentals because this is a single-name PT adjustment without new trial or regulatory information.

No clear regional spillover implied by the article.

Minimal global relevance, as the news is confined to one analyst’s valuation update.

Counterpoint

The unchanged Overweight rating suggests the broker still expects outperformance, so the PT cut may be more about valuation mechanics than deteriorating fundamentals.

Key entities

  • Phathom Pharmaceuticals

    Subject of the analyst update, with Barclays maintaining Overweight and lowering the price target to $10.

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.